Andreas von Deimling Selected Research

Glioma (Gliomas)

12/2022	HIP1R and vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma.
5/2022	Dysfunctional dendritic cells limit antigen-specific T cell response in glioma.
1/2022	T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas.
12/2021	GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types.
12/2021	Tumor cell plasticity, heterogeneity, and resistance in crucial microenvironmental niches in glioma.
1/2021	Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas.
1/2021	Comparative evaluation of T-cell receptors in experimental glioma-draining lymph nodes.
1/2021	A vaccine targeting mutant IDH1 in newly diagnosed glioma.
1/2021	Radiation-induced gliomas represent H3-/IDH-wild type pediatric gliomas with recurrent PDGFRA amplification and loss of CDKN2A/B.
1/2021	Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andreas von Deimling Research Topics

Disease

226	Neoplasms (Cancer) 12/2022 - 07/2002
103	Glioma (Gliomas) 12/2022 - 10/2004
90	Glioblastoma (Glioblastoma Multiforme) 05/2022 - 08/2002
39	Astrocytoma (Pilocytic Astrocytoma) 12/2022 - 08/2002
27	Brain Neoplasms (Brain Tumor) 01/2022 - 05/2006
20	Meningioma (Meningiomas) 12/2022 - 09/2006
17	Oligodendroglioma 12/2022 - 10/2004
17	Medulloblastoma 01/2022 - 03/2010
16	Melanoma (Melanoma, Malignant) 01/2022 - 02/2012
11	Neoplasm Metastasis (Metastasis) 11/2021 - 08/2004
11	Sarcoma (Soft Tissue Sarcoma) 01/2021 - 06/2011
11	Neurofibrosarcoma (MPNST) 01/2016 - 02/2004
9	Carcinogenesis 01/2020 - 04/2004
8	Disease Progression 11/2021 - 10/2005
7	Neuroblastoma 03/2020 - 05/2007
6	Carcinoma (Carcinomatosis) 11/2021 - 03/2005
5	Necrosis 01/2020 - 04/2009
5	Ependymoma 01/2017 - 03/2009
4	Solitary Fibrous Tumors 01/2022 - 05/2013
4	Primitive Neuroectodermal Tumors (PNET) 01/2021 - 01/2016
4	Neurilemmoma (Schwannoma) 01/2020 - 04/2014
4	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 09/2017 - 08/2010
4	Lung Neoplasms (Lung Cancer) 12/2014 - 02/2009
3	Chromosome Aberrations (Chromosome Abnormalities) 01/2022 - 03/2009
3	Lymphoma (Lymphomas) 01/2021 - 08/2004
3	Hemangiosarcoma (Angiosarcoma) 01/2021 - 04/2014
3	Genomic Instability 12/2019 - 01/2016
3	Chondrosarcoma 08/2018 - 04/2014
3	Inflammation (Inflammations) 04/2016 - 06/2007
3	Colorectal Neoplasms (Colorectal Cancer) 12/2014 - 02/2012
3	Breast Neoplasms (Breast Cancer) 12/2014 - 11/2003
3	Adenocarcinoma 11/2014 - 10/2013
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2014 - 06/2011

Drug/Important Bio-Agent (IBA)

72	Proteins (Proteins, Gene)FDA Link 12/2022 - 08/2002
55	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 05/2022 - 12/2008
44	DNA (Deoxyribonucleic Acid)IBA 12/2022 - 08/2002
34	Biomarkers (Surrogate Marker)IBA 12/2022 - 12/2007
30	Biological ProductsIBA 01/2022 - 08/2004
23	Temozolomide (Temodar)FDA LinkGeneric 01/2022 - 10/2005
20	ParaffinIBA 12/2022 - 09/2009
19	RNA (Ribonucleic Acid)IBA 10/2022 - 02/2004
17	Messenger RNA (mRNA)IBA 01/2020 - 03/2005
14	Formaldehyde (Formol)FDA Link 12/2022 - 11/2009
14	Pharmaceutical PreparationsIBA 12/2021 - 05/2007
13	EnzymesIBA 01/2021 - 09/2006
10	Histones (Histone)IBA 01/2019 - 01/2010
9	AntigensIBA 05/2022 - 02/2015
9	alpha-hydroxyglutarateIBA 10/2020 - 01/2012
8	MethyltransferasesIBA 01/2021 - 01/2011
8	Codon (Codons)IBA 01/2021 - 12/2008
8	LigandsIBA 01/2013 - 11/2003
7	Peptides (Polypeptides)IBA 01/2022 - 02/2006
7	ErbB Receptors (EGF Receptor)IBA 01/2021 - 12/2008
7	Tryptophan (L-Tryptophan)FDA Link 01/2021 - 10/2011
7	MicroRNAs (MicroRNA)IBA 01/2020 - 04/2009
6	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2021 - 12/2013
6	Phosphotransferases (Kinase)IBA 01/2020 - 01/2012
6	Small Interfering RNA (siRNA)IBA 04/2019 - 01/2008
6	Alkylating AgentsIBA 02/2016 - 01/2012
6	Monoclonal AntibodiesIBA 10/2015 - 01/2010
6	O(6)-Methylguanine-DNA MethyltransferaseIBA 07/2014 - 12/2009
5	NucleotidesIBA 11/2021 - 01/2016
5	Amino Acids FDA Link 01/2021 - 08/2002
5	VaccinesIBA 01/2021 - 08/2014
5	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 01/2021 - 10/2011
5	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 11/2020 - 12/2008
5	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2018 - 11/2008
5	Neurofibromin 1 (Neurofibromin)IBA 01/2016 - 07/2004
4	Neoplasm Antigens (Tumor Antigens)IBA 05/2022 - 11/2018
4	ProteomeIBA 01/2022 - 11/2018
4	ChromatinIBA 12/2019 - 01/2012
4	TensinsIBA 01/2018 - 09/2005
4	Mitogen-Activated Protein KinasesIBA 01/2018 - 03/2013
4	EpitopesIBA 01/2018 - 02/2015
4	Matrix Metalloproteinases (MMPs)IBA 01/2018 - 09/2006
4	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2018 - 02/2004
4	isocitric acid (isocitrate)IBA 09/2017 - 08/2010
4	Transcription Factors (Transcription Factor)IBA 01/2015 - 09/2006
4	Histone Deacetylase InhibitorsIBA 05/2014 - 01/2009
4	Mutant Proteins (Protein, Mutant)IBA 03/2013 - 02/2012
3	KynurenineIBA 01/2021 - 10/2011
3	Cyclin-Dependent Kinases (cdk Proteins)IBA 12/2020 - 12/2009
3	Bevacizumab (Avastin)FDA Link 10/2020 - 10/2015
3	SurvivinIBA 03/2020 - 11/2008
3	Interleukin-6 (Interleukin 6)IBA 01/2019 - 08/2010
3	Membrane Proteins (Integral Membrane Proteins)IBA 01/2019 - 09/2009
3	Fas Ligand Protein (Fas Ligand)IBA 01/2018 - 03/2008
3	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2018 - 09/2005
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2018 - 07/2010
3	Lomustine (CCNU)FDA Link 11/2017 - 12/2009
3	Tretinoin (Retinoic Acid)FDA LinkGeneric 10/2015 - 11/2003
3	Tyrosine Kinase InhibitorsIBA 11/2014 - 03/2006
3	AntibodiesIBA 08/2014 - 02/2004

Therapy/Procedure

80	Therapeutics 01/2022 - 07/2002
36	Radiotherapy 01/2022 - 01/2007
34	Drug Therapy (Chemotherapy) 01/2022 - 01/2005
9	Immunotherapy 05/2022 - 02/2015
8	Chemoradiotherapy 11/2016 - 03/2009
5	Aftercare (After-Treatment) 01/2021 - 05/2006
5	Ligation 02/2015 - 07/2010